iPSirius SAS, [pronounced ip-Sirius], is a French headquartered immuno-oncology firm, seeking to obtain a clinical trial authorization from the U.K.’s Medicines and Healthcare Regulatory Products Agency, to enable it to move its novel therapeutic cancer vaccine into a first-in-human trial in patients with non-small-cell lung cancer.
iPSirius: Illuminating the Path to Cancer Immunity
Company Details
- Employees
- 2
- Founded
- 2018
- Address
- 23 Rue Pierre Nicole, Paris,75005 Paris,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.ipsirius.co.uk
- HQ
- Paris
Ipsirius Questions
Ipsirius's website is http://www.ipsirius.co.uk
Ipsirius's LinkedIn profile is https://fr.linkedin.com/company/ipsirius75
Ipsirius has
2 employees.
View email and phone details for 2
employees at Ipsirius.
Ipsirius's industry is
Biotechnology Research
Ipsirius's top competitors are
Lindville Bio,
Oncovita,
Resolution Therapeutics,
Ucb,
Altevax Biotech,
Mnemo Therapeutics,
Plurify,
Scarcell Therapeutics,
Laverock Therapeutics,
Evexta Bio.
Ipsirius's categories are Biotechnology Research
Ipsirius's founding year is 2018
